Cardio quickPredict
Cardiotoxicity Screening
Commercial/ServiceActive
Key Facts
Indication
Cardiotoxicity Screening
Phase
Commercial/Service
Status
Active
Company
About Stemina Biomarker Discovery
Stemina Biomarker Discovery, founded in 2007 and based in Madison, Wisconsin, is a pioneer in human cell-based toxicology testing. The company's core technology is a metabolomics platform applied to human pluripotent stem cell-derived models, which powers its flagship assays for developmental toxicity (devTOX quickPredict) and cardiotoxicity (Cardio quickPredict). These assays provide faster, cheaper, and human-relevant safety data for pharmaceutical, chemical, and consumer product companies, positioning Stemina at the forefront of the New Approach Methodologies (NAMs) movement. The company also has a diagnostic arm, NeuroPointDX, focused on developing metabolomic tests for autism spectrum disorder.
View full company profileTherapeutic Areas
Other Cardiotoxicity Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Cardiac Toxicity Screening Model | Fluicell | Development/Commercial |